SCHEMBL4245563

SCHEMBL4245563

O=C(OCC1C2CN(Cc3ccccc3)CC12)N(Cc1ccccc1)c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.49
CHRM2 P08172 6/20 0.48
CHRM1 P11229 6/20 0.48
CHRM3 P20309 6/20 0.48
SIGMAR1 Q99720 2/20 0.44
OPRM1 P35372 1/20 0.44
KCNH2 Q12809 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PTGIR P43119 5/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
PTGDR Q13258 1/20 0.42
MAOB P27338 1/20 0.40
BCHE P06276 2/20 0.40
NPC1 O15118 1/20 0.39
JAK2 O60674 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4250571 0.90 CHRM2 (0.52) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4237606 0.90 CHRM2 (0.48) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4246952 0.86 CHRM2 (0.48) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4248307 0.86 CHRM2 (0.52) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4249813 0.84 ACHE (0.47) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4246887 0.84 CHRM1 (0.49) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4245844 0.83 ACHE (0.48) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4240764 0.80 CHRM1 (0.46) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4240894 0.79 CHRM2 (0.47) ACHECHRM2CHRM1CHRM3SIGMAR1
SCHEMBL4248347 0.79 CHRM2 (0.52) ACHECHRM2CHRM1CHRM3BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 ACHE 108/4885CHRM2 2/4885CHRM1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.